Concepts (123)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 9 | 2023 | 509 | 2.610 |
Why?
|
| Cachexia | 3 | 2024 | 51 | 1.800 |
Why?
|
| Neoplasms | 3 | 2024 | 769 | 1.370 |
Why?
|
| Disease Models, Animal | 4 | 2024 | 1406 | 0.800 |
Why?
|
| Acetate-CoA Ligase | 1 | 2022 | 8 | 0.800 |
Why?
|
| BRCA2 Protein | 1 | 2021 | 18 | 0.740 |
Why?
|
| Exosomes | 1 | 2023 | 86 | 0.730 |
Why?
|
| BRCA1 Protein | 1 | 2021 | 23 | 0.730 |
Why?
|
| Adenosine | 1 | 2021 | 33 | 0.720 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 375 | 0.660 |
Why?
|
| Signal Transduction | 6 | 2025 | 1374 | 0.640 |
Why?
|
| Receptors, Interleukin-8B | 1 | 2019 | 5 | 0.640 |
Why?
|
| Cell Line, Tumor | 9 | 2025 | 1271 | 0.640 |
Why?
|
| Stomach Neoplasms | 1 | 2019 | 19 | 0.630 |
Why?
|
| Cell Communication | 1 | 2019 | 66 | 0.610 |
Why?
|
| Cation Transport Proteins | 4 | 2025 | 60 | 0.570 |
Why?
|
| Macrophages | 1 | 2019 | 281 | 0.520 |
Why?
|
| Breast Neoplasms | 1 | 2021 | 447 | 0.500 |
Why?
|
| Zinc Finger E-box-Binding Homeobox 1 | 3 | 2021 | 26 | 0.490 |
Why?
|
| Mice | 10 | 2025 | 4472 | 0.470 |
Why?
|
| STAT3 Transcription Factor | 4 | 2025 | 93 | 0.430 |
Why?
|
| Humans | 14 | 2025 | 27175 | 0.410 |
Why?
|
| Animals | 10 | 2025 | 10082 | 0.350 |
Why?
|
| Cell Movement | 3 | 2021 | 353 | 0.330 |
Why?
|
| Prognosis | 2 | 2023 | 762 | 0.310 |
Why?
|
| Muscles | 2 | 2022 | 70 | 0.240 |
Why?
|
| Microglia | 1 | 2025 | 58 | 0.230 |
Why?
|
| Extracellular Vesicles | 1 | 2025 | 35 | 0.230 |
Why?
|
| Zinc | 2 | 2025 | 59 | 0.230 |
Why?
|
| Neoplasm Metastasis | 3 | 2021 | 151 | 0.230 |
Why?
|
| Glioblastoma | 1 | 2025 | 101 | 0.220 |
Why?
|
| Disease Progression | 3 | 2025 | 458 | 0.220 |
Why?
|
| Integrin alpha3 | 2 | 2021 | 18 | 0.210 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2023 | 29 | 0.210 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2021 | 110 | 0.210 |
Why?
|
| Neoadjuvant Therapy | 1 | 2023 | 69 | 0.200 |
Why?
|
| Lysosomes | 1 | 2023 | 55 | 0.200 |
Why?
|
| Models, Biological | 3 | 2021 | 448 | 0.200 |
Why?
|
| Dynamin II | 1 | 2022 | 12 | 0.200 |
Why?
|
| Tumor Necrosis Factors | 1 | 2022 | 14 | 0.200 |
Why?
|
| Adenosine Monophosphate | 1 | 2022 | 20 | 0.200 |
Why?
|
| Dextrans | 1 | 2022 | 22 | 0.200 |
Why?
|
| Syndecan-1 | 1 | 2022 | 12 | 0.200 |
Why?
|
| Glycogen Synthase Kinase 3 beta | 1 | 2022 | 40 | 0.200 |
Why?
|
| Combined Modality Therapy | 1 | 2023 | 293 | 0.200 |
Why?
|
| Tumor Microenvironment | 2 | 2025 | 159 | 0.200 |
Why?
|
| Phosphoprotein Phosphatases | 1 | 2022 | 38 | 0.190 |
Why?
|
| Brain Neoplasms | 1 | 2025 | 297 | 0.190 |
Why?
|
| Indoleamine-Pyrrole 2,3,-Dioxygenase | 1 | 2021 | 5 | 0.190 |
Why?
|
| Immune Evasion | 1 | 2021 | 7 | 0.190 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2022 | 106 | 0.190 |
Why?
|
| Transforming Growth Factor beta | 1 | 2022 | 77 | 0.180 |
Why?
|
| B7-H1 Antigen | 1 | 2021 | 35 | 0.180 |
Why?
|
| Precision Medicine | 1 | 2022 | 70 | 0.180 |
Why?
|
| Dexamethasone | 1 | 2021 | 54 | 0.180 |
Why?
|
| MicroRNAs | 2 | 2022 | 279 | 0.180 |
Why?
|
| Lipids | 1 | 2022 | 199 | 0.180 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 37 | 0.180 |
Why?
|
| Cell Plasticity | 1 | 2021 | 10 | 0.180 |
Why?
|
| Area Under Curve | 1 | 2021 | 94 | 0.180 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 154 | 0.180 |
Why?
|
| Tumor Burden | 1 | 2021 | 108 | 0.180 |
Why?
|
| ROC Curve | 1 | 2021 | 137 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2022 | 128 | 0.180 |
Why?
|
| Neoplasm Staging | 2 | 2019 | 463 | 0.180 |
Why?
|
| Prostaglandin D2 | 1 | 2020 | 6 | 0.180 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2021 | 189 | 0.180 |
Why?
|
| Proportional Hazards Models | 1 | 2021 | 217 | 0.170 |
Why?
|
| Proteomics | 1 | 2022 | 177 | 0.170 |
Why?
|
| Survival Analysis | 1 | 2021 | 279 | 0.170 |
Why?
|
| Immunosuppressive Agents | 1 | 2021 | 142 | 0.170 |
Why?
|
| Integrin beta1 | 1 | 2019 | 15 | 0.170 |
Why?
|
| Databases, Factual | 1 | 2021 | 253 | 0.170 |
Why?
|
| Muscle, Skeletal | 1 | 2024 | 622 | 0.170 |
Why?
|
| Immunotherapy | 1 | 2021 | 139 | 0.160 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2019 | 46 | 0.160 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2021 | 161 | 0.160 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2021 | 129 | 0.160 |
Why?
|
| Deoxycytidine | 1 | 2019 | 63 | 0.160 |
Why?
|
| Chemokine CXCL5 | 1 | 2019 | 5 | 0.160 |
Why?
|
| Chemokine CXCL1 | 1 | 2019 | 6 | 0.160 |
Why?
|
| Severity of Illness Index | 1 | 2021 | 448 | 0.160 |
Why?
|
| Coculture Techniques | 1 | 2019 | 54 | 0.160 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 445 | 0.160 |
Why?
|
| Cohort Studies | 1 | 2021 | 864 | 0.150 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2019 | 151 | 0.150 |
Why?
|
| Claudin-1 | 1 | 2018 | 7 | 0.150 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2018 | 17 | 0.150 |
Why?
|
| Biomarkers, Tumor | 1 | 2021 | 377 | 0.150 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 250 | 0.150 |
Why?
|
| Mutation | 1 | 2021 | 823 | 0.140 |
Why?
|
| Gene Expression | 1 | 2019 | 407 | 0.140 |
Why?
|
| Cell Proliferation | 4 | 2022 | 774 | 0.140 |
Why?
|
| Transcription Factors | 1 | 2021 | 514 | 0.140 |
Why?
|
| Adenocarcinoma | 1 | 2019 | 287 | 0.140 |
Why?
|
| Female | 2 | 2021 | 14658 | 0.120 |
Why?
|
| Spheroids, Cellular | 2 | 2021 | 53 | 0.080 |
Why?
|
| Heterografts | 2 | 2021 | 62 | 0.080 |
Why?
|
| Middle Aged | 1 | 2021 | 6918 | 0.080 |
Why?
|
| Male | 2 | 2021 | 13034 | 0.080 |
Why?
|
| Triggering Receptor Expressed on Myeloid Cells-1 | 1 | 2025 | 6 | 0.060 |
Why?
|
| Cyclin D1 | 1 | 2022 | 38 | 0.050 |
Why?
|
| Lymphocyte Count | 1 | 2021 | 14 | 0.050 |
Why?
|
| Databases, Genetic | 1 | 2021 | 47 | 0.050 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2021 | 57 | 0.050 |
Why?
|
| Protein Transport | 1 | 2021 | 153 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 180 | 0.040 |
Why?
|
| Pancreas | 1 | 2020 | 59 | 0.040 |
Why?
|
| Equilibrative Nucleoside Transporter 1 | 1 | 2019 | 15 | 0.040 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2019 | 33 | 0.040 |
Why?
|
| Fluorouracil | 1 | 2019 | 53 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2019 | 88 | 0.040 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2020 | 114 | 0.040 |
Why?
|
| Protein Binding | 1 | 2021 | 636 | 0.040 |
Why?
|
| Gene Knockdown Techniques | 1 | 2019 | 131 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2021 | 438 | 0.040 |
Why?
|
| Cisplatin | 1 | 2019 | 175 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2019 | 312 | 0.040 |
Why?
|
| Survival Rate | 1 | 2019 | 412 | 0.040 |
Why?
|
| Phosphorylation | 1 | 2019 | 567 | 0.040 |
Why?
|
| Apoptosis | 1 | 2021 | 738 | 0.040 |
Why?
|
| Immunohistochemistry | 1 | 2018 | 455 | 0.030 |
Why?
|
| Transcription, Genetic | 1 | 2018 | 400 | 0.030 |
Why?
|